|
|
 |
|
Viewing report
|
|
|
|
Thought Leader Insight & Analysis Report - Ovarian Cancer Q1 2010
Medpredict, Feb 2010, Pages: 146
Ovarian cancer is only one tenth as common as breast cancer, but the mortality associated with ovarian cancer is higher. There are 250,000 new cases diagnosed each year in the US, and at least 15,000 women die each year in the US from ovarian cancer. While the 5-year survival for non-metastatic disease is 75%, only 20% of metastatic patients live this long. Thus there is an urgent unmet need for improved treatment strategies for ovarian cancer.
This report summarizes the perspectives of 7 highly regarded ovarian cancer specialists (all US-based). In this report they provide their opinions on standards of care today and their expectations for experimental therapeutics. The “next big thing” will be Avastin, so the Panel evaluates inhibitors of PARP and mTOR/PI3K/AKT (& MEK) in a world where oncologists have moved from platinum doublets to a triplet containing bevacizumab, carboplatin and (paclitaxel / gemcitabine / doxorubicin). The Panel identifies strengths and weaknesses for lead compounds amongst the most important mechanisms in development for ovarian cancer.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
